Cargando…
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant preval...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661091/ https://www.ncbi.nlm.nih.gov/pubmed/29164151 http://dx.doi.org/10.1155/2017/9849823 |
_version_ | 1783274415791800320 |
---|---|
author | Li, Zhanyi Liu, Ying Zhang, Ying Shao, Xiaoqiong Luo, Qiumin Guo, Xiaoyan Lin, Guoli Cai, Qingxian Zhao, Zhixin Chong, Yutian |
author_facet | Li, Zhanyi Liu, Ying Zhang, Ying Shao, Xiaoqiong Luo, Qiumin Guo, Xiaoyan Lin, Guoli Cai, Qingxian Zhao, Zhixin Chong, Yutian |
author_sort | Li, Zhanyi |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant prevalent genotype; the data on the prevalence of naturally occurring RAVs in it is scarce. Our study aims to assess the prevalence of RAVs in treatment-naive HCV-6a patients. METHODS: Nested PCR assays were performed on 95 HCV-6a patients to amplify HCV viral regions of NS3, NS5A, and NS5B. RESULTS: In NS3/4A region, we detected Q80K in 95.5% isolates (84/88) and D168E in 2.3% isolates (2/88). In NS5A region, we detected Q30R in 93.2% isolates (82/88), L31M in 4.6% isolates (4/88), and H58P in 6.8% isolates (6/88). In NS5B region, we detected A15G in 2.3% isolates (2/88), S96T in 1.1% isolates (1/88), and S282T in 20.7% isolates (17/88) and we detected I482L in 100% isolates (4/4), V494A in 50% isolates (2/4), and V499A in 100% isolates (4/4). CONCLUSIONS: RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients. |
format | Online Article Text |
id | pubmed-5661091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-56610912017-11-21 Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients Li, Zhanyi Liu, Ying Zhang, Ying Shao, Xiaoqiong Luo, Qiumin Guo, Xiaoyan Lin, Guoli Cai, Qingxian Zhao, Zhixin Chong, Yutian Biomed Res Int Research Article BACKGROUND AND OBJECTIVE: The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant prevalent genotype; the data on the prevalence of naturally occurring RAVs in it is scarce. Our study aims to assess the prevalence of RAVs in treatment-naive HCV-6a patients. METHODS: Nested PCR assays were performed on 95 HCV-6a patients to amplify HCV viral regions of NS3, NS5A, and NS5B. RESULTS: In NS3/4A region, we detected Q80K in 95.5% isolates (84/88) and D168E in 2.3% isolates (2/88). In NS5A region, we detected Q30R in 93.2% isolates (82/88), L31M in 4.6% isolates (4/88), and H58P in 6.8% isolates (6/88). In NS5B region, we detected A15G in 2.3% isolates (2/88), S96T in 1.1% isolates (1/88), and S282T in 20.7% isolates (17/88) and we detected I482L in 100% isolates (4/4), V494A in 50% isolates (2/4), and V499A in 100% isolates (4/4). CONCLUSIONS: RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients. Hindawi 2017 2017-10-15 /pmc/articles/PMC5661091/ /pubmed/29164151 http://dx.doi.org/10.1155/2017/9849823 Text en Copyright © 2017 Zhanyi Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Zhanyi Liu, Ying Zhang, Ying Shao, Xiaoqiong Luo, Qiumin Guo, Xiaoyan Lin, Guoli Cai, Qingxian Zhao, Zhixin Chong, Yutian Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title_full | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title_fullStr | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title_full_unstemmed | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title_short | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients |
title_sort | naturally occurring resistance-associated variants to hepatitis c virus direct-acting antiviral agents in treatment-naive hcv genotype 6a-infected patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661091/ https://www.ncbi.nlm.nih.gov/pubmed/29164151 http://dx.doi.org/10.1155/2017/9849823 |
work_keys_str_mv | AT lizhanyi naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT liuying naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT zhangying naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT shaoxiaoqiong naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT luoqiumin naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT guoxiaoyan naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT linguoli naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT caiqingxian naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT zhaozhixin naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients AT chongyutian naturallyoccurringresistanceassociatedvariantstohepatitiscvirusdirectactingantiviralagentsintreatmentnaivehcvgenotype6ainfectedpatients |